Trials / Completed
CompletedNCT00767637
Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone
Open Label, Non-controlled Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone in Patients With Hyperphosphatemia Receiving Dialysis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanthanum Carbonate (BAY77-1931) | BAY77-1931 750mg, in the morning, day and evening |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-10-07
- Last updated
- 2014-06-20
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00767637. Inclusion in this directory is not an endorsement.